Pharmaceuticals

Definium Therapeutics

The Hill and Definium Therapeutics Host Forum on Psychedelic Therapy Prospects

Definium Therapeutics Completes First Patient Dosing in DT120 ODT for Major Depressive Disorder Phase 3 Clinical Trial

Definium Therapeutics plans five Phase III studies for DT120 ODT targeting GAD and MDD

Definium Therapeutics Inc Reports Q1 EPS of $(0.71)

Definium Therapeutics released FY2026 Q1 earnings on May 7 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7099 (forecast USD -0.4953)

Definium Therapeutics to Release FY2026 Q1 Earnings on May 7 During-Market EST, Forecast EPS USD -0.4953

Definium Therapeutics Outlines Late-Stage Development Plans for DT120

Oppenheimer analyst reiterates buy rating on Definium Therapeutics

Definium Therapeutics Announces Clinical Trial Progress for DT120 ODT

Definium Therapeutics Expected to Obtain Major Drug Clinical Trial Results in 2026

Definium Therapeutics released FY2025 earnings on February 26 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -2.0599 (forecast USD -1.9807)

Definium Therapeutics released FY2025 Q4 earnings on February 26 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5001 (forecast USD -0.4638)

Definium Therapeutics to Release FY2025 Q4 Earnings on February 26 After-Market (EST), Forecast EPS -0.4758 USD

Definium Therapeutics Launches LSD Promotion Campaign for Psychiatry

Definium Therapeutics Inc. released FY2024 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.671

Definium Therapeutics Inc. released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7831 (forecast USD -0.5)

Definium Therapeutics Inc. released FY2024 Q3 earnings on November 6, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.2747 (forecast USD -0.2987)

DFTX.US released FY2025 9 Months Earnings on November 6, 2025 (BJT) with actual revenue of USD 0 and EPS of USD -1.6324

Definium Therapeutics Inc. released FY2025 Semi-Annual Earnings on July 31 (EST), with actual revenue of USD 0 and EPS of USD -0.8135

Definium Therapeutics Inc. released FY2024 Q2 earnings on July 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2562 (forecast USD -0.325)

Co-Diagnostics

Netcapital

NewGenIvf

Liminatus Pharma

Agape ATP

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Wheeler Real Estate

Sunshine Biopharma

DFTX

Definium has released an updated corporate presentation detailing its Phase 3 DT120 ODT program, with three topline readouts expected in 2026. The company reported $373.4 million in cash and equivalents as of March 31, 2026, with a cash runway projected into 2028. The presentation also highlights Phase 2b results showing effective single-dose outcomes in GAD and MDD, and ongoing Phase 2a studies for DT402 (R(-)-MDMA).

TradingView

Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash

A forum hosted by The Hill and Definium Therapeutics will discuss the potential of psychedelic treatments for mental health issues, addressing the economic impact of mental illness in the U.S. and the need for innovative therapies. With several psychedelic medicines in late-stage trials and receiving FDA Breakthrough Therapy Designation, the event aims to inform lawmakers and advocates on the regulatory landscape and necessary actions to support patients.

Thehill

Watch live: Rethinking Psychedelic Treatment for America's Mental Health Crisis

LifeSci Capital's Francois Brisebois has maintained a Buy rating on Definium Therapeutics (DFTX) with a price target of $38.00. The analyst consensus suggests a Strong Buy rating for the stock, with an average price target of $40.00. Brisebois has an average return of 2.4% and a 40.11% success rate on his recommendations.

Tip Ranks

Savara

Praxis Precision Medicines

Opus Genetics

LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)

Definium Therapeutics (NASDAQ:DFTX) reported Q1 earnings of ($0.71) EPS, missing estimates of ($0.48) by ($0.23). The company has three pivotal DT120 ODT phase III trials nearing completion, with significant cash reserves of $373.4 million to fund operations through 2028. The stock traded down to $22.05, with a market cap of $2.20 billion. Analyst ratings vary, with target prices ranging from $20 to $70. Hedge funds have increased their stakes in the company, which focuses on developing treatments for brain health disorders.

Market Beat

Oppenheimer

ROYAL BANK OF CANADA

BNP Paribas

Definium Therapeutics (NASDAQ:DFTX) Issues Earnings Results

Definium Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results. Also, Piper Sandler lowered its price target on the stock from $49 to $48.

benzinga_article

Piper Sandler Cos

Earnings Watch

Definium Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0